<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; C</title>
	<atom:link href="http://www.tapanray.in/tag/c/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Leverage Increased Focus On ‘Self-Care’ For Better Patient Outcomes</title>
		<link>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leverage-increased-focus-on-self-care-for-better-patient-outcomes</link>
		<comments>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/#comments</comments>
		<pubDate>Mon, 24 Jan 2022 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infectious]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[messaging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[non-infectious]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[ovid-19]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-care]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10640</guid>
		<description><![CDATA[‘People have been practicing self-care for thousands of years. Now an increase in self-care interventions is shifting the way health care is perceived, understood, and accessed, and adding to the many medicines, diagnostics, and technologies available for people to use &#8230; <a href="http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hepatitis C: A Silent, Deadly Disease: Treatment Beyond Reach of Most Indians</title>
		<link>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians</link>
		<comments>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/#comments</comments>
		<pubDate>Mon, 04 Aug 2014 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[cirrhosis]]></category>
		<category><![CDATA[D]]></category>
		<category><![CDATA[E]]></category>
		<category><![CDATA[Egypt]]></category>
		<category><![CDATA[executive]]></category>
		<category><![CDATA[fibrosis]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[HCV]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[hepatocellular carcinoma]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infected]]></category>
		<category><![CDATA[inhibitor]]></category>
		<category><![CDATA[interferon]]></category>
		<category><![CDATA[IOM]]></category>
		<category><![CDATA[John]]></category>
		<category><![CDATA[liver]]></category>
		<category><![CDATA[Martin]]></category>
		<category><![CDATA[Metropolis]]></category>
		<category><![CDATA[NCDC]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pegylated]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[protease]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ribavitin]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[virus]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5697</guid>
		<description><![CDATA[Every year, July 28 is remembered as the ‘World Hepatitis Day’. In India, this year too, the day had gone by virtually uneventful, for various reasons. This happened despite increasing trend of the disease in the country. Though, there are &#8230; <a href="http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hepatitis-c-a-silent-deadly-disease-treatment-beyond-reach-of-most-indians/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The ‘TINA Factor’: A Hotspot for Patented Drugs</title>
		<link>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-tina-factor-a-hotspot-for-patented-drugs</link>
		<comments>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/#comments</comments>
		<pubDate>Mon, 16 Dec 2013 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alternative]]></category>
		<category><![CDATA[Andre]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[foist]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TINA]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[virus]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4555</guid>
		<description><![CDATA[An article published in a global business magazine on December 5, 2013 mentioned that Marijn Dekkers, the CEO of Bayer AG reportedly has said at the Financial Times Global Pharmaceutical &#38; Biotech Conference held this month that: “Bayer didn’t develop its cancer drug, Nexavar (sorafenib) for &#8230; <a href="http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
